Analysed ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) News Sources
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
13-04-2026
yahoo.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
07-04-2026
yahoo.com
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
30-03-2026
yahoo.com
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
15-03-2026
marketbeat.com
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
10-02-2026
yahoo.com
What is the current price of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The current price of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is $14.02.
ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) since the previous trading day is $-0.04.
ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) since the previous trading day is -0.2845%.
What is the most recent average sentiment score for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The most recent average sentiment score for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)?
The most recent sentiment for ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ) is .
SEC-8K** Filing Available For ENANTA PHARMACEUTICALS INC (ENTA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.